Immunic (NASDAQ:IMUX) Earns Sell (D-) Rating from Weiss Ratings

Immunic (NASDAQ:IMUX)‘s stock had its “sell (d-)” rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently commented on IMUX. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday, September 26th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, September 25th. Finally, Chardan Capital started coverage on shares of Immunic in a research report on Monday, September 29th. They set a “buy” rating and a $13.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Immunic Trading Up 2.0%

IMUX opened at $0.90 on Wednesday. Immunic has a 1-year low of $0.56 and a 1-year high of $1.73. The company has a market cap of $88.54 million, a P/E ratio of -0.95 and a beta of 1.56. The company has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $0.91.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, research analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. 683 Capital Management LLC grew its position in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after purchasing an additional 200,000 shares in the last quarter. Focus Partners Wealth grew its position in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after purchasing an additional 415,104 shares in the last quarter. Finally, Aberdeen Group plc bought a new stake in Immunic in the 1st quarter worth about $1,155,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.